Noxopharm Limited
OTC: NOXOF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gisela Mautner
- Headquarters
- Chatswood, Australia
- IPO year
- 2020
- Market cap
- $14.8M
- Website
- https://www.noxopharm.com
Loading NOXOF…
Loading profile data…Frequently asked questions about NOXOF
What does Noxopharm Limited (NOXOF) do?
Noxopharm Limited, a pharmaceutical company, is focused on developing therapeutic solutions for a range of solid tumor cancers and septic shock, catering to both Australian and international markets. Its primary asset, Veyonda, is currently being developed as an adjuvant therapy, intended to complement chemotherapy and radiotherapy in the treatm...
Where does NOXOF trade?
Noxopharm Limited (NOXOF) trades on the Other OTC.
What sector is NOXOF in?
Noxopharm Limited (NOXOF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Noxopharm Limited?
Gisela Mautner is the chief executive officer of Noxopharm Limited (NOXOF).
Where is Noxopharm Limited headquartered?
Noxopharm Limited is headquartered in Australia.
Does NOXOF pay a dividend?
Noxopharm Limited (NOXOF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NOXOF go public?
Noxopharm Limited (NOXOF) completed its initial public offering in 2020.